Brought to you by 
AZ and Incyte investigate combo therapy for NSCLC
03 Jan 2022
Executive Summary
AstraZeneca PLC and Incyte Corp. have come together again, this time to study a combination of Incyte's INCB39110 with AZ's Tagrisso (osimertinib) for non-small cell lung cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ and Incyte investigate combo therapy for NSCLC
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice